Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Endocrine
Published in: Endocrine 1/2013

01-08-2013 | Original Article

Interleukin-7 expression in tears and orbital tissues of patients with Graves’ ophthalmopathy

Authors: KeBo Cai, RuiLi Wei

Published in: Endocrine | Issue 1/2013

Login to get access

Abstract

The aim of this study was to explore whether IL-7 participates in the pathogenesis of Graves’ ophthalmopathy (GO). This was a prospective study. 20 GO patients (40 eyes) and 20 healthy volunteers (40 eyes) were recruited. The tear concentration of IL-7 was measured using ELISA assay. IL-7 expression in orbital tissues was evaluated by immunohistochemistry. Patients with inactive GO had the highest IL-7 concentrations in the tears, followed by healthy controls and patients with active GO per ELISA. Immunohistochemistry analysis showed that IL-7 expression in orbital tissues of the inactive GO samples was higher than that of the volunteers. Changes of IL-7 expression in different phases of GO suggested that IL-7 may play an important role in the pathogenesis of GO.
Literature
1.
J.A. Garrity, R.S. Bahn, Pathogenesis of graves ophthalmopathy: implications for prediction, prevention, and treatment. Am. J. Ophthalmol. 142, 147–153 (2006)PubMedCrossRef
2.
L. Bartalena, A. Pinchera, C. Marcocci, Management of Graves’ ophthalmopathy: reality and perspectives. Endocr. Rev. 21, 168–199 (2000)PubMedCrossRef
3.
M.V. Brasil, O.F. Brasil, R.P. Vieira et al., Tear film analysis and its relation with palpebral fissure height and exophthalmos in Graves’ ophthalmopathy. Arq. Bras. Oftalmol. 68, 615–618 (2005)PubMedCrossRef
4.
G. Iskeleli, Y. Karakoc, A. Abdula, Tear film osmolarity in patients with thyroid ophthalmopathy. Jpn. J. Ophthalmol. 52, 323–326 (2008)PubMedCrossRef
5.
A.K. Khurana, S. Sunder, B.K. Ahluwalia, Tear film profile in Graves’ ophthalmopathy. Acta Ophthalmol. (Copenh) 70, 346–349 (1992)CrossRef
6.
R.H. Chen, W.C. Chen, C.T. Chang et al., Interleukin-1-beta gene, but not the interleukin-1 receptor antagonist gene, is associated with Graves’ disease. J. Clin. Lab. Anal. 19, 133–138 (2005)PubMedCrossRef
7.
8.
R. Hofmeister, A.R. Khaled, N. Benbernou et al., Interleukin-7: physiological roles and mechanisms of action. Cytokine Growth Factor Rev. 10, 41–60 (1999)PubMedCrossRef
9.
A. Bikker, C.E. Hack, F.P. Lafeber et al., Interleukin-7: a key mediator in T cell-driven autoimmunity, inflammation, and tissue destruction. Curr. Pharm. Des. 18, 2347–2356 (2012)PubMedCrossRef
10.
A. Link, T.K. Vogt, S. Favre et al., Fibroblastic reticular cells in lymph nodes regulate the homeostasis of naive T cells. Nat. Immunol. 8, 1255–1265 (2007)PubMedCrossRef
11.
T. Junt, E. Scandella, B. Ludewig, Form follows function: lymphoid tissue microarchitecture in antimicrobial immune defence. Nat. Rev. Immunol. 8, 764–775 (2008)PubMedCrossRef
12.
R. Mazzucchelli, S.K. Durum, Interleukin-7 receptor expression: intelligent design. Nat. Rev. Immunol. 7, 144–154 (2007)PubMedCrossRef
13.
R. Rübenhagen, J.P. Schüttrumpf, K.M. Stürmer et al., Interleukin-7 levels in synovial fluid increase with age and MMP-1 levels decrease with progression of osteoarthritis. Acta Orthop. 83, 59–64 (2012)PubMedCrossRef
14.
A.M. Crawley, J.B. Angel, The influence of HIV on CD127 expression and its potential implications for IL-7 therapy. Semin. Immunol. 24, 231–240 (2012)PubMedCrossRef
15.
L. Vassena, H. Miao, R. Cimbro et al., Treatment with IL-7 prevents the decline of circulating CD4 + T cells during the acute phase of SIV infection in rhesus macaques. PLoS Pathog. 8, e1002636 (2012)PubMedCrossRef
16.
O. Yamaji, T. Nagaishi, T. Totsuka et al., The development of colitogenic CD4 (+) T cells is regulated by IL-7 in collaboration with NK cell function in a murine model of colitis. J. Immunol. 15, 2524–2536 (2012)CrossRef
17.
S. Koyasu, K. Moro, Role of innate lymphocytes in infection and inflammation. Front Immunol. 3, 101 (2012)PubMedCrossRef
18.
C. Penaranda, W. Kuswanto, J. Hofmann et al., IL-7 receptor blockade reverses autoimmune diabetes by promoting inhibition of effector/memory T cells. Proc. Natl. Acad. Sci. U S A 109, 12668–12673 (2012)PubMedCrossRef
19.
G.B. Bartley, C.A. Gorman, Diagnostic criteria for Graves’ ophthalmopathy. Am. J. Ophthalmol. 119, 792–795 (1995)PubMed
20.
D. Huang, N. Xu, Y. Song et al., Inflammatory cytokine profiles in the tears of thyroid-associated ophthalmopathy. Graefes Arch. Clin. Exp. Ophthalmol. 250, 619–625 (2012)PubMedCrossRef
21.
A.G. Gianoukakis, N. Khadavi, T.J. Smith, Cytokines, Graves’ disease, and thyroid-associated ophthalmopathy. Thyroid 18, 953–958 (2008)PubMedCrossRef
22.
B. Ujhelyi, P. Gogolak, A. Erdei et al., Graves’ orbitopathy results in profound changes in tear composition: a study of plasminogen activator inhibitor-1 and seven cytokines. Thyroid 22, 407–414 (2012)PubMedCrossRef
23.
L. van Steensel, H. Hooijkaas, D. Paridaens et al., PDGF enhances orbital fibroblast responses to TSHR stimulating autoantibodies in Graves’ ophthalmopathy patients. J. Clin. Endocrinol. Metab. 97, E944–E953 (2012)PubMedCrossRef
24.
A.M. Avunduk, M.C. Avunduk, H. Pazarli et al., Immunohistochemical analysis of orbital connective tissue specimens of patients with active Graves ophthalmopathy. Curr. Eye Res. 30, 631–638 (2005)PubMedCrossRef
25.
J.R. Wall, M. Salvi, N.F. Bernard et al., Thyroid-associated ophthalmopathy–a model for the association of organ-specific autoimmune disorders. Immunol. Today 12, 150–153 (1991)PubMed
26.
27.
Y. Hiromatsu, H. Kaku, I. Miyake et al., Role of cytokines in the pathogenesis of thyroid-associated ophthalmopathy. Thyroid 12, 217–221 (2002)PubMedCrossRef
28.
R. Moncayo, I. Baldissera, C. Decristoforo et al., Evaluation of immunological mechanisms mediating thyroid-associated ophthalmopathy by radionuclide imaging using the somatostatin amalog111In-octreotide. Thyroid 7, 21–29 (1997)PubMedCrossRef
29.
A.K. Eckstein, M. Plicht, H. Lax et al., Thyrotropin receptor autoantibodies are independent risk factors for Graves’ ophthalmopathy and help to predict severity and outcome of the disease. J. Clin. Endocrinol. Metab. 91, 3464–3470 (2006)PubMedCrossRef
30.
S.L. Trokel, F.A. Jakobiec, Correlation of CT Scanning and pathologic features of ophthalmic Graves’ disease. Ophthalmology 88, 553–564 (1981)PubMed
31.
H.A. Khalil, R.J. De Keizer, V.M. Bodelier et al., Secretory IgA and lysozyme in tears of patients with Graves’ ophthalmopathy. Doc. Ophthalmol. 72, 329–334 (1989)PubMedCrossRef
32.
A. Gupta, P.B. Sadeghi, E.K. Akpek, Occult thyroid eye disease in patients presenting with dry eye symptoms. Am. J. Ophthalmol. 147, 919–923 (2009)PubMedCrossRef
33.
K.L. Komschlies, K.J. Grzegorzewski, R.H. Wiltrout, Diverse immunological and hematological effects of interleukin-7: implication for clinical application. J. Leukoc. Biol. 58, 623–633 (1995)PubMed
34.
F. Simonetta, N. Gestermann, K.Z. Martinet et al., Interleukin-7 influences FOXP3+CD4+ regulatory T cells peripheral homeostasis. PLoS ONE 7, E36596 (2012)PubMedCrossRef
35.
M. Pellegrini, T. Calzascia, J.G. Toe et al., IL-7 engages multiple mechanisms to overcome chronic viral infection and limit organ pathology. Cell 144, 601–613 (2011)PubMedCrossRef
36.
A. Ryden, K. Stechova, M. Durilova et al., Switch from a dominant Th1-associated immune profile during the pre-diabetic phase in favour of a temporary increase of a Th3-associated and inflammatory immune profile at the onset of type 1 diabetes. Diabetes Metab. Res. Rev. 25, 335–343 (2009)PubMedCrossRef
37.
S.R. Pickens, N.D. Chamberlain, M.V. Volin et al., Characterization of interleukin-7 and interleukin-7 receptor in the pathogenesis of rheumatoid arthritis. Arthritis Rheum. 63, 2884–2893 (2011)PubMedCrossRef
38.
R. Liaria, B. Giacomina, G. Eva et al., IL-7 up-regulates TNF-α-dependent osteoclastogenesis in patients affected by solid tumor. PLoS ONE 1, 1–9 (2006)CrossRef
39.
M. Pellegrini, TW. Tumor immune therapy: lessons from infection and implications for cancer can IL-7 help overcome immune inhibitory networks? Eur. J. Immunol. 40, 1852–1861 (2010)PubMedCrossRef
40.
M. Huang, S. Sharma, L.X. Zhu et al., IL7 inhibits fibroblast TGF-β production and signaling in pulmonary fibrosis. J. Clin. Invest. 109, 931–937 (2002)PubMed
41.
L. Zhang, M.P. Keane, L.X. Zhu et al., Interleukin-7 and transforming growth factor-β play counter-regulatory roles in protein kinase C-dependent control of fibroblast collagen synthesis in pulmonary fibrosis. J. Biol. Chem. 279, 28315–28319 (2004)PubMedCrossRef
42.
L. Koumas, T.J. Smith, S. Feldon et al., Thy-1 expression in human fibroblast subsets defines myo-fibroblastic or lipofibroblastic phenotypes. Am. J. Pathol. 163, 1291–1300 (2003)PubMedCrossRef
43.
A. Grigorian, H. Mkhikian, M. Demetriou, Interleukin-2, interleukin-7, T cell-mediated autoimmunity, and N-glycosylation. Ann. N. Y. Acad. Sci. 1253, 49–57 (2012)PubMedCrossRef
44.
C.M. Henriques, J. Rino, R.J. Nibbs et al., IL-7 induces rapid clathrin-mediated internalization and JAK3-dependent degradation of IL-7Ralpha in T cells. Blood 115, 3269–3277 (2010)PubMedCrossRef
Metadata
Title
Interleukin-7 expression in tears and orbital tissues of patients with Graves’ ophthalmopathy
Authors
KeBo Cai
RuiLi Wei
Publication date
01-08-2013
Publisher
Springer US
Published in
Endocrine / Issue 1/2013
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-012-9840-7

Other articles of this Issue 1/2013

Endocrine 1/2013 Go to the issue

Review

Extracellular vesicles as an emerging mechanism of cell-to-cell communication

Original Article

BRAF V600E associates with cytoplasmatic localization of p27kip1 and higher cytokeratin 19 expression in papillary thyroid carcinoma

Original Article

Regulatory T cells and plasmacytoid dendritic cells contribute to the immune escape of papillary thyroid cancer coexisting with multinodular non-toxic goiter

Original Article

Two novel mutations in CYP11B1 and modeling the consequent alterations of the translated protein in classic congenital adrenal hyperplasia patients

Original Article

Combination therapy with risedronate and teriparatide in male osteoporosis

Original Article

Expression and significance of IGF-1 and IGF-1R in thyroid nodules
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits